eye disease
| 4 min read
7-methylxanthine is being reformulated into a sustained-release oral therapy aimed at improving long-term control of axial elongation in childhood myopia.
| 3 min read
PolyActiva and RareSight are pairing pro-drug chemistry with targeted ocular delivery to address early-stage barriers in rare pediatric retinal disorders.
| 3 min read
These latest deals give Lilly a complementary portfolio of life-changing therapies and scalable gene therapy platforms.
| 3 min read
A novel eye drop from LENZ Therapeutics represents the first time the FDA has approved aceclidine, a cholinergic agonist, in any drug.
| 8 min read
Explore how suprachoroidal injection is a groundbreaking new macular degeneration treatment. Learn how it offers a safer, more targeted alternative to a traditional subretinal injection.
| 4 min read
A new method called “REVeRT” expands the capabilities of gene delivery platforms by transporting larger genes than previously possible.
| 10+ min read
Eye injections are the only way to treat diabetic retinopathy, but many refuse to get them. Now, eye drops and pills are on their way.
| 10+ min read
Between invasive surgery or risky laser therapy, people suffering from severe eye floaters have no great treatment options. Now, with the development of a safer and less invasive nanoparticle-based therapy, people with floaters may finally get their vision and quality of life back.
| 3 min read
The acquisition includes clinical stage anti-IGF-1R monoclonal antibody VRDN-001, which is intended for treatment of thyroid eye disease
Page 1 of 1 - 9 Total Items
